Background: MicroRNAs (miRNAs) have emerged as key players in various human biological processes, including tumorigenesis. Here, we investigated the roles of miR-375 in the pathogenesis of oral squamous cell carcinoma (OSCC). Methods: We performed quantitative real-time PCR (qRT-PCR) to detect miR-375 expression in OSCC tissues and corresponding normal oral epithelial tissues and analyze the correlation of miR-375 expression with OSCC metastasis and patient's survival. Then, the effects of miR-375 expression on proliferation, cell cycle, apoptosis and radiosensitivity in OSCC cells were determined by using MTT, flow cytometry and clonogenic survival assays. A dual-luciferase reporter assay was performed to test whether miR-375 binds to the 3'-untranslated region (3'-UTR) of target mRNA. Results: The expression level of miR-375 in OSCC tissues was significantly lower than that in normal oral epithelial tissues, and low miR-375 expression was correlated with higher incidence of lymph node metastasis and poor survival of OSCC patients. Upregulation of miR-375 significantly inhibits growth, induces cell cycle arrest in G 0 /G 1 phase, increases apoptosis and enhances radiosensitivity in OSCC cells. Analysis of luciferase activity demonstrated that miR-375 binds to the 3'-UTR of insulin like growth factor 1 receptor (IGF-1R). Small interfering RNA (shRNA)-mediated IGF-1R knockdown mimics the effects of miR-375 upregulation, while overexpression of IGF-1R partially reverses those effects in OSCC cells. Conclusion: It was obviously demonstrated that miRNA-375 inhibits growth and enhances radiosensitivity in OSCC cells by targeting IGF-1R, suggesting that miR-375 may be a potential therapeutic target for OSCC patients.
MicroRNA-375 Inhibits Growth and Enhances Radiosensitivity in Oral

Introduction
Oral squamous cell carcinoma (OSCC), the most common cancer of the head and neck, is one of the leading causes of oral cancer-related death around the world due to poor prognosis [1] . Much progress made in OSCC therapy by surgery, chemo-or radiotherapy, but the 5-year survival rate of OSCC still remains under 60%. Similar to other tumors, the pathogenesis of OSCC is a complicated process involving multiple events and steps [2] . Some molecular pathogenesis studies have been undertaken successfully, however the carcinogenic mechanism of OSCC still remains poorly understood. Thus, it is urgent for us to understand the molecular bases of OSCC development to identify potential molecular therapeutic targets for the treatment of OSCC.
MicroRNAs (miRNAs), a class of small non-coding RNAs, negatively regulate gene expression at post-transcription level through their base-pairing with the 3'-untranslated region (3'-UTR) [3, 4] . Accumulating evidence has indicated that deregulation of miRNAs plays a critical role in a variety of physiological and biological processes and many other diseases, including cancer [5] [6] [7] . Some dysregulated miRNAs have been reported to be correlated with OSCC development. By analysis of the miRNA expression profiles of OSCC tumors and normal oral mucosal samples, Soga' et al showed that OSCC tissues have a unique miRNA profile pattern when compared with that in normal tissues [8] . In another study, Manikandan' et al identified 46 miRNAs that were differentially expressed in OSCC [9] . Likewise, Siow' et al identified 15 upregulated and 4 downregulated miRNAs in OSCC as compared with normal tissues and miR-375 was validated as the most down-regulated miRNA [10] . Yoon and his colleagues investigated the prognostic value of miR-375 and miR-214-3p in early stage OSCC, and testified the model consisting of a two-miR panel with age and gender may be useful in prognostic significance of early stage OSCC patients [11] . Shi' et al also testified the potential involvement of miR-375 in the premalignant progression of OSCC [12] . Although above results clearly indicated that reduced miR-375 may contribute to OSCC development, the effect of miR-375 on phenotypes of OSCC cells is unclear and needs to be further elucidated.
In this study, our results indicated that miR-375 is downregulated in OSCC tissues compared with adjacent normal oral epithelial tissues. Also, reduced miR-375 is observed to be correlated with poorer prognosis of OSCC patients. Upregulation of miR-375 significantly inhibits growth and enhances radiosensitivity in OSCC cells by targeting IGF-1R. Our findings indicate that targeting miR-375 may be utilized as a potential strategy for radiosensitization of human OSCCs.
Materials and Methods
Tumor tissues A total of 44 paired of resected OSCC and corresponding normal oral epithelial tissues were collected from patients who were diagnosed at the Department of Oral and Maxillofacial Surgery in Jiangsu Province and Nanjing oral medical hospital from 2008 to 2010. Ethical approval was obtained from the hospital and fully informed consent from all patients prior to sample collection. None of all patients had received chemotherapy or radiotherapy before surgery. All tissue samples were confirmed by pathological examinations. Fresh frozen tissues were stored in liquid nitrogen until use. Clinical parameters, including pathological features and TNM stage, were retrospectively col lected by reviewing patients' charts. This study was approved by the Review Board of Hospital Ethics Committee
Cell culture
The human OSCC cell line (SCC-4) was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO-BRL) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomyc in a humidified atmosphere of 5% CO 2 and 95% air at 37°C.
Quantitative real-time PCR (qRT-PCR) assay
Total RNA was extracted from the tissues or cultured cells using Trizol (Invitrogen, CA, USA) following the manufacturer's instruction and reverse transcribed using Taqma™ microRNA reverse transcription kit and subjected to real-time PCR using TaqMan™ MicroRNA Assay kit (Applied Biosystems, USA) according to the manufacturer's instructions as described previously [13] . Reactions were performed using Stratagene Mx3000 instrument in triplicate. The expression of miRNA was defined based on the threshold cycle (Ct), and relative expression levels were calculated as 2 -[(Ct of miR-375)-(Ct of U6)] after normalization with reference to expression of U6 small nuclear RNA.
Transfection of oligonucleotides or plasmids
All miR-375/mimics (or miR-NC/mimics) or miR-375/inhibitor (or miR-NC/inhibitor) were all chemically synthesized by GenePharma (Shanghai, China). For IGF-1R interfering, shRNA targeting IGF-1R (shRNA-IGF-1R) (5'-CUGACUACAGGGAUCUCAU-3') and negative control shRNA (shRNA-control) (5'-GAUCUACGGCAGUCUAUCA-3') were inserted into pLMP vector, which were named pLMP/shRNA-IGF-1R or pLMP/shRNA-control, respectively. The plasmid vector (pcDNA/IGF-1R) expressing open-reading frame of IGF-1R was successfully constructed. For transient transfectionm, SCC-4 cells were plated in 6-well plates and transfected with 100 nM of miR-375/mimics (or miR-NC/mimics) or miR-375/inhibitor (or miR-NC/ inhibitor) using Lipofectamine 2000 (Invitrogen, Long Island, NY) according to the manufacturer's protocol. For stable knockdown of IGF-1R, SCC-4 cells were transfected with pLMP/shRNA-IGF-1R or pLMP/shRNAcontrol using Lipofectamine 2000 and were selected with 5.0 μg/mL of puromycin (Sigma, USA), which were named SCC-4/shRNA-IGF-1R or SCC-4/shRNA-control, respectively.
Western blot assay
Proteins were extracted from the fresh tissues and cultured cells with a protein extraction kit (KeyGEN, Nanjing) and separated in 10% SDS polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membranes (Roche), then detected with anti-human IGF-1R and GAPDH antibodies (Santa Cruz, Dallas, TX, USA). Protein loading was estimated using mouse anti-GAPDH monoclonal antibody. Lab WorksTM Image Acquisition and Analysis Software (UVP, Upland, CA, USA) were used to quantify band intensities.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
The cell proliferation was detected using MTT assay as described previously [14] . Briefly, the transfected SCC-4 cells were seeded in a 96-well plate. The plates were incubated for 24, 48, 72, 96 or 120 hours, and each well was added with 25 μL of MTT (10 mg/mL) and incu bated for 4 h. Then, the supernatant was removed, and 150 μL of dimethyl sulfoxide was added to each well (Sigma, USA). After an overnight incubation, absorbance at 490nm was measured using a microplate reader (Bio-Rad, CA, USA).
Clonogenic survival assay
The clonogenic survival assay was performed as described previously [15] . Briefly, the cells were seeded in triplicate at limiting dilutions in 6-well plates for about 24 hours until attached. 24 hours later, the cells were irradiated with different doses of X-ray radiation (0, 2.0, 4.0, 6.0, and 8.0 Gy), respectively. The medium was replaced with a fresh one 24 hours after irradiation. After 7 days of incubation, the colonies were fixed with methanol, stained with 0.5% crystal violet in absolute ethanol and colonies with ≥50 cells were counted under dissection microscope. In each irradiation dose group, surviving fraction of cells was calculated as plating efficiency of the irradiated cells divided by the plating efficiency of the irradiated cells by that of mock control.
Flow cytometric detection of cell cycle and apoptosis
Flow cytometry assay was performed to detect the changes of cell cycle and apoptosis described previously [16] . In brief, the transfected cells were fixed with 70% ethanol and treated with 1 mg/mL RNase at 37°C for 30 min. Then, the cells were stained with propidium iodide (PI; 50 μg/mL; Sigma) at 4°C for 30 min. Subsequently, the cell cycle and apoptosis were analyzed with a FACS flow cytom eter (BD Biosciences, CA, USA). Dual luciferase activity assay Dual luciferase activity assay was performed as described previously [17] . In brief, The luciferase-3'-UTR-wild-type (wt) reporter (pGL3-IGF-1R/3'-UTR-wt) or luciferase-3'-UTR-mutant (mut) (pGL3-IGF-1R/3'-UTR-mut) plasmids were prepared by inserting the IGF-1R/3'-UTR-wt carrying a putative miR-375 binding site or its mutant sequence into the pGL3-control plas mid (Promega, Madison, WI, USA). SCC-4 cells were seeded in a 48-well plate and co-transfected with miR-375/mimics or miR-NC/mimics, and pGL3 firefly luciferase vectors containing wild-type or mutant IGF-1R/3'-UTR sequence using Lipofectamine 2000. Cotransfected with two days post-transfection, the cells were collected and lysed for measurement of luciferase activities using the Dual-Luciferase Assay kit (Promega, Madison, WI) according the manufacturer's protocol.
Statistical analysis
All statistical analyses were performed using the SPSS 17.0 statistical software package (SPSS, Inc., Chicago, IL, USA). Experimental data were expressed as the mean±SEM. The differences between groups were analyzed using a Student t test when only 2 groups or 1-way analysis of variance when more than 2 groups were compared. Bivariate correlations were calculated by Spearman's Rank Correlation Coefficients. Kaplan-Meier method was used to draw the survival curve, and log-rank test was used for survival analysis. A P value of less than 0.05 was considered statistically significant.
Results
Reduced miR-375 is observed to be correlated with tumor progression and poor prognosis of OSCC patients
To explore the relationship between miR-375 expression and OSCC, the expression of miR-375 was detected in 44 paired of OSCC tissues and corresponding normal oral epithelial tissues using qRT-PCR. As shown in Fig. 1A , the expression level of miR-375 was significantly reduced in OSCC tissues compared with normal oral epithelial tissues (P<0.001). Also, the expression of miR-375 was observed to be downregulated in OSCC tissues with lymph node metastasis (n=18) compared with tissues without lymph node metastasis (n=26) (P<0.001; Fig. 1B) . Furthermore, the OSCC patients with low miR-375 expression level (n=19) had poorer overall survival rate than those patients with high miR-375 lev el (n=25) (P=0.0076; Fig. 1C ). These results suggested that reduced miR-375 may play a role in OSCC development. (Fig. 2B) . Upregulation of miR-375 significantly reduced growth in SCC-4 cells, while downregulation of miR-375 moderately promoted growth in SCC-4 cells. Then, we performed flow cytomery to detect the changes of cell cycle and apoptosis. Results of cell cycle analysis showed that transfection of miR-375/mimics induced the increased accumulation in G 0 /G 1 phase and decreased accumulation in S phase but no obvious changes in G 2 /M phase (Fig. 2C) . Meanwhile, the apoptotic rate of miR-375/mimics-transfected SCC-4 cells was increased by about 19.32%, compared with the control group (P<0.05; Fig.  2D ). Furthermore, we investigated the effect of miR-375 expression on radiosensitivity in OSCC cells. In SCC-4 cells, the survival rate was observed to be reduced in 2.0, 4.0, 6.0 and 8.0-Gy-irradiated SCC-4/miR-375/mimics cells, when compared with SCC-4/miR-NC/ mimics cells (Fig. 2E) . However, the survival rate in 4.0, 6.0 and 8.0 Gy-irradiated SCC-4/ miR-375/inhibitor cells was observed to be increased, in comparison with the control group (Fig. 2F) . In addition, after the transfected cells were treated with irradiation (2.0, 4.0, 6.0 or 8.0Gy), the apoptosis was determined. Upregulation of miR-375 significantly enhanced irradiation-induced apoptosis in SCC-4 cells (Fig. 2G) , while downregulation miR-375 reduced irradiation-induced apoptosis in SCC-4 cells (Fig. 2H) . These results suggest that upregulation of miR-375 inhibits growth, induces cell cycle arrest in G 0 /G 1 phase, increases apoptosis and enhances radiosensitivity in OSCC cells.
miR-375 directly targets IGF-1R in OSCC cells
To better understand the mechanisms of miR-375 function in OSCC, we performed a bioinformatics (two algorithms: TargetScan and PicTar) search for potential targets of miR-375 and IGF-1R was selected for further analysis. A complementary sequence of miR-375 to the 3'-UTR of IGF-1R mRNA (position: 7423-7429nt) is shown in Fig. 3A . Although IGF-1R has been identified as a direct target of miR-375 in laryngeal squamous cell cancer and cervical cancer [18, 19] , whether miR-375 targets IGF-1R to function in OSCC cells is unclear. First, the dual-lucifer ase reporter assay was performed and the luciferase activity was determined (Fig. 3B) . The relative luciferase activity of the luciferase reporter fused to the wild-type of IGF-1R/3'-UTR (IGF-1R/3'-UTR-wt) was significantly reduced (P<0.01) when miR-375/ mimics was co-transfected into SCC-4 cells. However, the luciferase activity in cells with the reporter gene fused to the mutated-type of IGF-1R/3'-UTR (IGF-1R/3'-UTR-mut) showed no obvious changes (P>0.05). Then, qRT-PCR and Western blot assays were performed to analyze the effects of miR-375 expression on IGF-1R mRNA and protein expression in SCC- (Fig. 3C-D) . The data indicated that IGF-1R is a direct target of miR-375 in OSCC cells.
miR-375 functions in OSCC cells partially by targeting IGF-1R
We further confirm that IGF-1R is a functional target of miR-375 in OSCC cells. (Fig. 4A) . Functional assays indicated that shRNA-mediated IGF-1R downregulation significantly reduced the capacities of growth, induced cell arrest in G 0 /G 1 phase and enhanced apoptosis in SCC-4 cells (Fig. 4B-D) . Moreover, the effect of IGF-1R downregulation on radiosensitivity (Fig. 4E) . After those transfected SCC-4 cells were treated with irradiation (2.0, 4.0, 6.0 or 8.0 Gy), the apoptosis was determined. Results showed that IGF-1R downregulation significantly increased irradiation-induced apoptosis in SCC-4 cells (Fig. 4F) . These data suggested that silencing of IGF-1R mimics the effects of miR-375 upregulation on growth, apoptosis and radiosensitivity in OSCC cells. Then, we performed IGF-1R rescue experiments. Overexpression of IGF-1R reverses the downregulation of IGF-1R mRNA and protein in SCC-4 cells induced by miR-375/mimics (Fig. 5A-B) . Meanwhile, overexpression of IGF-1R partially reverses the effects of miR-375 upregulation on growth and apoptosis in SCC-4 cells (Fig. 5C-D) . Furthermore, co-transfection of pcDNA/IGF-1R and miR-375/mimics partially reverses growth inhibition and apoptosis enhancement in miR-375/mimics-transfected SCC-4 cells with irradiation treatment (4.0 and 6.0 Gy) (Fig. 5E-F) . From above data, it was concluded that miR-375 functions in OSCC cells, at least partially targeting IGF-1R.
Expression of IGF-1R mRNA inversely correlates with miR-375 expression in OSCC tissues
Then, we performed qRT-PCR to detect the expression of IGF-1R mRNA in 40 paired of OSCC tissues and corresponding normal oral epithelial tissues. It was observed that the expression level of IGF-1R mRNA in OSCC tissues was significantly higher than that in corresponding normal oral epithelial tissues (P=0.004; Fig. 6A ). Meanwhile, the expression level of IGF-1R mRNA in OSCC tissues with lymph node metastasis (n=16) was also higher than that in OSCC tissues without lymph node metastasis (n=24) (P=0.012; Fig. 6B ). Next, we per formed a correlation test using the above OSCC tissues, and showed that there was a significant inverse correlation between miR-375 and IGF-1R mRNA (r=-0.37, P<0.001; Fig.  6C ), suggesting that a regulatory relationship between miR-375 and IGF-1R may be present in OSCC. 
Discussion
In the present study, we showed that miR-375 is downregulated in OSCC tissues and reduced miR-375 is correlated with higher incidence of lymph node metastasis and poor prognosis of OSCC patients. Also, miR-375 inhibits growth, increases apoptosis and enhances radiosensitivity in OSCC cells, at least partially by targeting IGF-1R. The dysregulation of miR-375/IGF-1R axis might play important roles in OSCC development.
MiR-375 has been shown to function as a tumor suppressor in various human cancers. For example, Lian' et al reported that miR-375 functions as a tumor-suppressor gene in gastric cancer by targeting recepteur d'Origine Nantais [20] . Xu and his colleagues showed that miR-375 suppresses human colorectal cancer metastasis by directly acting upon Frizzled 8, suggesting that this miRNA may serve as a new therapeutic target to inhibit colorectal cancer metastasis [21] . In another report, miR-375 is also found to inhibit the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes [22] . Osako' et al also showed that miR-375 markedly inhibits cancer cell migration and invasion by regulation of MMP13 by in esophageal squamous cell carcinoma [23] . Jung and his colleagues showed that four anti-cancer drugs (doxorubicin, 5-fluorouracil, trichostatin A and etoposide) could induce the expression of tumor suppressor miR-375 in tongue cancer [24] . This research group also testified that underexpression of tumor suppressor miR-375 contributes to promoting cancerous phenotypes by inducing uncontrolled CIP2A expression and extended stability of MYC [25] . Meanwhile, they showed that miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ [26] . Although miR-375 downregulation in oral premalignant lesions is found to be associated with a higher risk of malignant transformation [27] , the functions of miR-375 in OSCC development are unclear. Here, we showed that miR-375 is significantly downregulated in OSCC tissues and the level of miR-375 expression could be used as a biomarker to distinguish patients with or without lymph node metastasis. OSCC patients with low miR-375 expression had shorter survival than those with high miR-375 expression. Next, we analyzed the effect of miR-375 expression on growth, cell cycle and apoptosis of OSCC cells. Ectopic expression of miR-375 inhibits growth, induces cell cycle arrest in G 0 /G 1 phase and enhances apoptosis in OSCC cells, while downregulation of miR-375 promotes OSCC cell growth. Recently, some researches also show that miR-375 exerts effect on the sensitivity of tumor treatments. For example, miR-375 is reported to be involved in development of chemoresistance of multiple tumor cells, such as prostate cancer, breast cancer, pancreatic cancer and gastric cancer [28] [29] [30] [31] , suggesting that miR-375 might serve as potential predictive biomarkers to chemotherapy and/or therapeutic targets to overcome chemoresistance in human cancers. Meanwhile, the correlation of miR-375 with radiosensitivity of tumor cells is also reported. For example, Song et al showed that miR-375 modulates radiosensitivity of HR-HPV-positive cervical cancer cells by targeting UBE3A through the p53 pathway [32] . Zhang and his colleagues showed that targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation, implying the development of miR-375 as a novel therapeutic agent to treat MYCN-amplified neuroblastoma [33] . In this study, we also analyzed the effect of miR-375 expression on radiosensitivity of OSCC cells, and showed that upregulation of miR-375 significantly enhances the sensitivity of OSCC cells to irradiation treatment by increasing irradiation-induced apoptosis, suggesting that targeting miR-375 might be a strategy for the treatment of radioresistant OSCC.
MiRNAs exert their functions through partially binding the mRNA, so identification of functional mRNA targets of miR-375 is important for understanding the roles of miR-375 in OSCC progression. By bioinformatics, IGF-1R gene was identified as a potential target of miR-375. In laryngeal squamous cell cancer and cervical cancer, IGF-1R has been testified as a functional target of miR-375 [18, 19] . IGF-1R belongs to the insulin receptor (IR) family which includes the IR, IGF-1R, IGF-1R/IR, and IGF-2R. Previous studies have shown that the IGF-1R signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies [34,3 5] . It is well known that IGF-1R exerts its main actions through the activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. Also, activation of IGF-1R is reported to be correlated with increased radioresistance by associating to new partners as major vault proteins (BCL-2, BAX, or Ku70/80), which are correlated with radiochemoresistance [36] . A previous study has shown that autocrine production of IGF-2, together with over-expression of IGF-1R, may be important components controlling the proliferation of OSCC cells [37] . Lara and his colleagues showed that low IGF-1R tumour expression was correlated to better long-term survival in patients suffering locally advanced oral carcinoma [38] . Recently, IGF-1R is testified as a target of let-7b and mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of OSCC [39] . However, whether miR-375 exerts its functions in OSCC by directly targeting IGF-1R is unclear. Here, luciferase assay indicated that miR-375 could bind to the 3'-UTR of IGF-1R mRNA. Additionally, alteration in miR-375 levels affects expression of IGF-1R both mRNA and protein. Most importantly, silencing of IGF-1R mimics the effects of miR-375 upregulation and overexpression of IGF-1R partially rescues the effects of miR-375 upregulation in OSCC cells. Also, there was a significant inverse correlation between miR-375 and IGF-1R mRNA in OSCC tissues. These results demonstrate that miR-375/IGF-1R regulatory axis might play a role in promotion of OSCC progression. As a single microRNA can potentially regulate multiple mRNA targets, whether miR-375 functions in OSCC cells by targeting other mRNAs needs to be elucidated in future study. Also, the mechanisms by which miR-375 and IGFR can affect radiosensitivity of OSCC cells need to be elucidated in future study.
Taken together, our study showed that reduced miR-375 is correlated with OSCC progression and poor survival of patients. Functional experiments indicated that miR-375 inhibits growth, increases apoptosis and enhances radiosensitivity in OSCC cells, at least partially by targeting IGF-1R. Therefore, miR-375 may be a potential therapeutic molecular target for OSCC therapy.
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